Elderly lung cancer patients: what treatment strategies?

References

• Yancik R, Ries L. Cancer in older persons: an international issue in an aging world. Semin. Oncol.31(2), 128–136 (2004).
   PubMed Web of Science ®Google Scholar
• Extermann M. Interaction between comorbidity and cancer. Cancer Control14(1), 13–22 (2007).
   PubMedGoogle Scholar
• Anisimov VN. Biology of aging and cancer. Cancer Control14(1), 23–31 (2007).
   PubMedGoogle Scholar
• Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med.341(27), 2061–2067, (1999).
   PubMed Web of Science ®Google Scholar
• Talarico L, Chen G, Pazdur R. Enrolment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J. Clin. Oncol.22(22), 4626–4631 (2004).
   PubMed Web of Science ®Google Scholar
• Balducci L. Geriatric oncology: challenges for the new century. Eur. J. Cancer36(14), 1741–1754 (2000).
   PubMed Web of Science ®Google Scholar
• Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J. Clin. Oncol.16(4), 1582–1587 (1998).
   PubMed Web of Science ®Google Scholar
• Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J.11(6), 449–460 (2005).
   PubMed Web of Science ®Google Scholar
• Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J.11(6), 461–473 (2005).
   PubMed Web of Science ®Google Scholar
• Fried LP, Tangen CM, Walston Jet al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci.56(3), M146–M156 (2001).
   PubMed Web of Science ®Google Scholar
• Balducci L. Aging, frailty, and chemotherapy. Cancer Control14(1), 7–12 (2007).
   PubMedGoogle Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J. Clin. Oncol.24(28), 4539–4544 (2006).
   PubMed Web of Science ®Google Scholar
• The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer. J. Natl Cancer Inst.91(1), 66–72 (1999).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J. Natl Cancer Inst.95(5), 362–372 (2003).
   PubMed Web of Science ®Google Scholar
• Kudoh S, Takeda K, Nakagawa K et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJOG 9904). J. Clin. Oncol.24(22), 3657–3663 (2006).
   PubMed Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol.22(2), 330–353 (2004).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Aapro M, Ardizzoni A et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international export panel. J. Clin. Oncol.23(13), 3125–3137 (2005).
   PubMed Web of Science ®Google Scholar
• Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J.311(7010), 899–909 (1995).
   PubMed Web of Science ®Google Scholar
• Fruh M, Tribodet H, Pignon JP et al. A pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung cancer. J. Clin. Oncol.25(Suppl. 18), S397 (2007) (Abstract 7553).
   Google Scholar
• Pepe C, Hasan B, Winton TL et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J. Clin. Oncol.25(12), 1553–1561 (2007).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly. J. Clin. Oncol.25(14), 1898–1907 (2007).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355(24), 2542–2550 (2006). Erratum in: N. Engl. J. Med.356(3), 318 (2007).
   PubMed Web of Science ®Google Scholar
• Jackman D, Yeap YB, Lindeman IN et al. Phase II clinical trial of chemotherapy naïve patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J. Clin. Oncol.25(7), 760–766 (2007).
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Dahlberg SE, Langer CJ et al. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. J. Clin. Oncol.25(Suppl. 18), S393 (2007) (Abstract 7535).
   Google Scholar